生物医药专利密集型产业发展现状及建议*——以上海市为例

目的: 就上海生物医药产业的产业发展现状及专利情况,基于宏观数据分析,提出相应的建议。方法: 通过对比国内各省市生物医药产业和专利数据,聚焦分析上海生物医药产业发展现状、经济贡献及专利布局。结果: 我国已初步形成以长三角、环渤海为核心,珠三角、川渝等地区快速发展的产业空间格局,上海生物医药产业中浦东新区则居于领先地位,高校院所是生物医药领域专利的申请主体。结论: 上海应优化产业承载空间,强化发展要素集聚,深入推进从“点状突破”到“链式创新”,建设生物医药集聚区,加快技术研发与产业化落地。     

干细胞专利价值评估与转移转化对策研究 *

Objective: To construct an indicator model for stem cell patent evaluation and to analyze the factors affecting stem cell patent transfer and transformation in real scenarios besides the indicators.Methods:Based on the Patent Value Analysis Indicator System edited by China Technology Exchange, a patent evaluation system suitable for stem cells patents was constructed. The weight was determined by AHP, and the operability of the indicator model was verified by case analysis.Results:Based on the technical characteristics of stem cell technologies and operability, an indicator system for evaluating stem cell patents was constructed, which included three first-level indicators including technical value, market value and legal value, and nine second-level indicators such as technological advancement, technological maturity, technological cost, et al. Technological advancement, technological maturity, policy adaptability and market demand were the four most influential indicators for the valuation of stem cell patents. In the analysis of other factors, the core advantage of the stem cell technologies was the key to affect the transformation of stem cell patents. In addition, technical feasibility, quality control and long-term benefits also had important impact on the successful transfer and transformation of stem cell technologies.Conclusion:The patent value evaluation model and factor analysis established can be used in stem cell patent evaluation, which is helpful to promote the effective development and industrialization of the patent technology.     

生物医药专利密集型产业发展现状及建议*——以上海市为例

目的: 就上海生物医药产业的产业发展现状及专利情况,基于宏观数据分析,提出相应的建议。方法: 通过对比国内各省市生物医药产业和专利数据,聚焦分析上海生物医药产业发展现状、经济贡献及专利布局。结果: 我国已初步形成以长三角、环渤海为核心,珠三角、川渝等地区快速发展的产业空间格局,上海生物医药产业中浦东新区则居于领先地位,高校院所是生物医药领域专利的申请主体。结论: 上海应优化产业承载空间,强化发展要素集聚,深入推进从“点状突破”到“链式创新”,建设生物医药集聚区,加快技术研发与产业化落地。     

单克隆抗体技术相关专利分析

单克隆抗体（monoclonal antibody,McAb）是来自单个B淋巴细胞或一个杂交瘤细胞克隆的只识别某一种特定抗原表位（抗原决定簇）的抗体,因具有高度的特异性和均一性,且能大量制备,从而为抗体的研究和应用带来了突破,     

间充质干细胞治疗产品开发现状与趋势

目的:从产品开发角度分析间充质干细胞治疗产品的发展现状和未来趋势。方法:检索科睿唯安(Clarivate Analytics)的Cortellis数据库的数据,利用定量分析法和对比分析法对检索结果进行分析。结果:目前已有5种间充质干细胞治疗产品上市,9种间充质干细胞治疗产品处于注册及临床Ⅲ期,未来市场上的间充质干细胞治疗产品将呈现快速增长趋势。Mesoblast、FCB等公司在间充质干细胞治疗产品的拥有量上具有优势。间充质干细胞产业内部的商业交易也越来越多,目前共发生包括药物开发及商业化许可、专利资产出售以及早期药物研发合作等12起交易,其中药物开发及商业化许可是最主要的交易模式。尽管中国的间充质干细胞治疗产品研究尚处于起步阶段,但中国的西比曼生物、北科生物等公司已有多款产品处于临床阶段,中国本土的间充质干细胞治疗产品前景可期。结论:虽然间充质干细胞治疗产品市场尚处于起步阶段,但其技术发展快,市场需求大,相关企业产品研发与商品化积极性高,上升潜力巨大。